Adaptimmune Therapeutics Plc Stock Price To Book
| ADAP Stock | USD 0.84 0.03 3.45% |
Adaptimmune Therapeutics Plc fundamentals help investors to digest information that contributes to Adaptimmune Therapeutics' financial success or failures. It also enables traders to predict the movement of Adaptimmune Stock. The fundamental analysis module provides a way to measure Adaptimmune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptimmune Therapeutics stock.
As of 10/19/2024, Price To Book Ratio is likely to grow to 4.24. Adaptimmune | Price To Book |
Adaptimmune Therapeutics Plc Company Price To Book Analysis
Adaptimmune Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Adaptimmune Therapeutics Price To Book | 2.24 X |
Most of Adaptimmune Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptimmune Therapeutics Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptimmune Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Adaptimmune Therapeutics is extremely important. It helps to project a fair market value of Adaptimmune Stock properly, considering its historical fundamentals such as Price To Book. Since Adaptimmune Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adaptimmune Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adaptimmune Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Adaptimmune Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Adaptimmune Therapeutics Plc has a Price To Book of 2.2354 times. This is 91.3% lower than that of the Biotechnology sector and 62.99% lower than that of the Health Care industry. The price to book for all United States stocks is 76.49% higher than that of the company.
Adaptimmune Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptimmune Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics of similar companies.Adaptimmune Therapeutics is currently under evaluation in price to book category among its peers.
Adaptimmune Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptimmune Therapeutics from analyzing Adaptimmune Therapeutics' financial statements. These drivers represent accounts that assess Adaptimmune Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptimmune Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 126.0M | 767.9M | 584.3M | 235.4M | 159.5M | 151.5M | |
| Enterprise Value | 101.0M | 734.7M | 459.8M | 150.4M | 40.7M | 38.7M |
Adaptimmune Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | 0.54 % | ||||
| Current Valuation | 47.77 M | ||||
| Shares Outstanding | 255.74 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 61.20 % | ||||
| Number Of Shares Shorted | 6.09 M | ||||
| Price To Earning | (7.73) X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 1.52 X | ||||
| Revenue | 60.51 M | ||||
| Gross Profit | (100.58 M) | ||||
| EBITDA | (127.91 M) | ||||
| Net Income | (114.31 M) | ||||
| Cash And Equivalents | 199.67 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 25.23 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 4.00 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (141.43 M) | ||||
| Short Ratio | 5.92 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Price To Earnings To Growth | 0.11 X | ||||
| Target Price | 2.56 | ||||
| Number Of Employees | 449 | ||||
| Beta | 2.19 | ||||
| Market Capitalization | 215.52 M | ||||
| Total Asset | 282.62 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 134.76 M | ||||
| Current Asset | 199.54 M | ||||
| Current Liabilities | 22.66 M | ||||
| Net Asset | 282.62 M |
About Adaptimmune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptimmune Therapeutics Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | DYAI | Dyadic International | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Adaptimmune Stock
| 0.71 | GNFT | Genfit | PairCorr |
| 0.66 | GILD | Gilead Sciences | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
| 0.58 | WVE | Wave Life Sciences | PairCorr |
| 0.41 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.